Efficacy and Safety of Favipiravir and Ribavirin Formulation for Treatment of COVID-19

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2021
This is a national, multicenter, open-label, randomized, phase II/III trial that evaluates the efficacy and safety of favipiravir and ribavirin in the treatment of patients with confirmed COVID-19 observed within 72 hours. Approximately 100 patients will be randomized in 1:1 ratio and divided into two groups.
Epistemonikos ID: ea1d5bea209f4a7548f966cfd05b4dcd6f06a43e
First added on: Apr 03, 2021